Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Infectious Disease

Monitoring Your Safety and Progress

At a Glance

During tuberculosis treatment, your medical team will closely monitor you for medication side effects, such as liver toxicity and vision changes. You will likely isolate at home initially and provide monthly sputum samples until tests confirm the bacteria are gone and you are no longer contagious.

While TB medications are life-saving, they are powerful drugs that require careful monitoring. Your medical team will use a combination of blood tests, eye exams, and lab samples to ensure the treatment is killing the bacteria while keeping your body safe.

Protecting Your Liver (And Understanding Your Urine)

Three of the four standard TB drugs—Isoniazid, Rifampin, and Pyrazinamide—can cause hepatotoxicity, which is a type of liver injury [1].

  • Liver Function Tests (LFTs): You will have regular blood tests to check your liver enzymes (such as AST and ALT) [2]. These tests are especially critical during the first 8 weeks of treatment [2][1].
  • The “Orange Fluid” Rule: Rifampin will turn your urine, sweat, and tears bright orange or red [3]. This is perfectly normal and harmless.
  • When to Call the Doctor: Do not confuse orange urine with liver damage. However, if your urine becomes dark, brownish, or “tea-colored”, or if you notice yellowing of the skin or eyes (jaundice), persistent nausea, or pain in the upper right side of your belly, contact your doctor immediately [4][5].
  • Alcohol Warning: Do not drink alcohol during your TB treatment. Alcohol severely increases the strain on your liver and heightens the risk of permanent damage [6].

Monitoring Your Vision

The drug Ethambutol can sometimes cause a condition called optic neuropathy (EON), which is damage to the nerve that connects your eye to your brain [7][8].

  • Baseline and Beyond: Before starting ethambutol, you should have a baseline eye exam. Your vision (clarity and color) should then be checked regularly while you are on the drug [9][4].
  • Symptoms of EON: If you notice colors looking “washed out” (especially red and green) or if your vision becomes blurry or has blind spots, stop taking the medication and call your doctor immediately [4][10]. If caught early, the vision changes are often reversible [11].

Managing At-Home Isolation

If you have active pulmonary TB, you will likely be asked to isolate at home for the first few weeks of your treatment. Isolation can feel daunting, but following simple rules will keep your family safe:

  • Airflow is Key: Stay in a well-ventilated room by yourself, keeping the door closed and opening a window if the weather allows.
  • Sleeping: Sleep in a separate bedroom from your spouse or family members.
  • Masking: If you must enter common areas of the house or travel to a medical appointment, you should wear an N95 or standard surgical mask (depending on your doctor’s guidance) to trap bacteria when you cough or speak. Your family does not necessarily need to wear masks if you are appropriately isolated and masked, but follow your public health worker’s specific instructions.
  • Remember: TB is not spread by sharing food, plates, or bathrooms [12]. You do not need to throw away your belongings.

Tracking Success: Sputum Conversion

How do doctors know the treatment is working? They look for sputum conversion [13].

  • The Process: Every month, you will provide a sample of your phlegm (sputum).
  • The Goal: Eventually, the lab will no longer find any TB bacteria in your sample. This “conversion” from positive to negative is the best sign that the medicine is winning [14][15].
  • Ending Isolation: While you usually become much less contagious within the first few weeks of effective treatment, doctors often wait for a negative sputum result before officially clearing you to end isolation and return to work or public activities [16].

Life After TB: Long-Term Health

Finishing your 6-month treatment is a huge milestone. Some survivors experience Post-Tuberculosis Lung Disease (PTLD), which is lingering scarring or damage to the lungs even after the bacteria are gone [17][18].

  • Follow-up: You may need periodic breathing tests or X-rays to monitor your lung function [19].
  • Rehabilitation: If you feel short of breath after treatment, pulmonary rehabilitation—a program of exercise and breathing techniques—can significantly improve your energy and quality of life [20][21].

Return to Understanding Your TB Diagnosis

Common questions in this guide

Is it normal for my urine to turn orange during TB treatment?
Yes. The TB drug Rifampin will harmlessly turn your urine, sweat, and tears bright orange or red. However, you should contact your doctor immediately if your urine becomes dark or tea-colored, as this can indicate liver damage.
Why do I need eye exams while taking TB medication?
The drug Ethambutol can sometimes cause optic neuropathy, affecting the nerve that connects your eye to your brain. Regular vision checks help catch early signs like blurry vision or washed-out colors, which are often reversible if caught early.
When can I safely stop isolating during TB treatment?
You will need to isolate until your sputum tests are negative for TB bacteria. Your doctor will use these monthly phlegm tests to confirm the medication is working and that you are no longer contagious before clearing you to end isolation.
What are the signs of liver damage from TB drugs?
Warning signs of liver injury include dark or tea-colored urine, yellowing of the skin or eyes, persistent nausea, and pain in the upper right side of your belly. Contact your doctor right away if you experience any of these symptoms.
Will my lungs fully recover after I finish TB treatment?
While treatment cures the active infection, some patients experience post-tuberculosis lung disease, which involves lingering scarring. If you have shortness of breath after treatment, pulmonary rehabilitation can help improve your lung capacity and energy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often will I have blood tests for my liver, and what specific numbers are you looking at?
  2. 2.Can you help me schedule my baseline vision test before I take my first dose of ethambutol?
  3. 3.When will we start checking my sputum for 'conversion' to negative?
  4. 4.At what point will it be safe for me to be around my family or go back to work?
  5. 5.After I finish my 6 months of treatment, what kind of follow-up tests will I need for my lung health?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia.

    Molla Y, Wubetu M, Dessie B

    Hepatic medicine : evidence and research 2021; (13()):1-8 doi:10.2147/HMER.S290542.

    PMID: 33536799
  2. 2

    Incidence and risk factors of abnormal liver function and anti-tuberculosis drug-induced liver injury: a multicenter retrospective study involving 482 chinese pediatric tuberculosis patients.

    Zhou Y, Wang M, Xu H, et al.

    Annals of medicine 2025; (57(1)):2546701 doi:10.1080/07853890.2025.2546701.

    PMID: 41219178
  3. 3

    Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.

    Bastos ML, Campbell JR, Oxlade O, et al.

    Annals of internal medicine 2020; (173(3)):169-178 doi:10.7326/M19-3741.

    PMID: 32539440
  4. 4

    Ethambutol and its ophthalmic effects; is screening and collaboration the new way forward?

    Vyas A, Subramanyam A, Phatak S, Tiwari S

    The Indian journal of tuberculosis 2024; (71(1)):30-34 doi:10.1016/j.ijtb.2023.03.009.

    PMID: 38296388
  5. 5

    Behçet's disease with latent Mycobacterium tuberculosis infection.

    Shen Y, Ma H, Luo D, et al.

    Open medicine (Warsaw, Poland) 2021; (16(1)):14-22 doi:10.1515/med-2021-0002.

    PMID: 33336078
  6. 6

    Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study.

    Feleke BE, Feleke TE, Adane WG, Girma A

    Virology journal 2020; (17(1)):113 doi:10.1186/s12985-020-01385-z.

    PMID: 32703225
  7. 7

    Clinical profile and visual outcomes in ethambutol-induced toxic optic neuropathy.

    Sheth J, Sachdeva V, Goyal A, et al.

    Indian journal of ophthalmology 2025; (73(Suppl 3)):S484-S491 doi:10.4103/IJO.IJO_1807_24.

    PMID: 40444310
  8. 8

    Prevalence and Incidence of Ethambutol-Induced Optic Neuropathy and Its Risk Factors in Korea: A Nationwide Population-Based Study.

    Lee S, Ryu WY, Kang D, Lee JK

    Journal of Korean medical science 2025; (40(20)):e65 doi:10.3346/jkms.2025.40.e65.

    PMID: 40425190
  9. 9

    Prospective evaluation of ethambutol toxic optic neuropathy in patients of pulmonary tuberculosis.

    Sharma N, Gahlot A, Goyal JL, et al.

    The Indian journal of tuberculosis 2025; (72(1)):69-73 doi:10.1016/j.ijtb.2023.11.001.

    PMID: 39890374
  10. 10

    Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy.

    Saxena R, Singh D, Phuljhele S, et al.

    Indian journal of ophthalmology 2021; (69(12)):3734-3739 doi:10.4103/ijo.IJO_3746_20.

    PMID: 34827033
  11. 11

    Incidence and prognostic factor of ethambutol-related optic neuropathy: 10-year experience in southern Taiwan.

    Chen SC, Lin MC, Sheu SJ

    The Kaohsiung journal of medical sciences 2015; (31(7)):358-62.

    PMID: 26162816
  12. 12

    Treatment of Drug-Susceptible Tuberculosis.

    Zha BS, Nahid P

    Clinics in chest medicine 2019; (40(4)):763-774 doi:10.1016/j.ccm.2019.07.006.

    PMID: 31731983
  13. 13

    A time-to-event modelling of sputum conversion within two months after antituberculosis initiation among drug-susceptible smear positive pulmonary tuberculosis patients: Implementation of internal and external validation.

    Muda MR, Albitar O, Harun SN, et al.

    Tuberculosis (Edinburgh, Scotland) 2024; (148()):102553 doi:10.1016/j.tube.2024.102553.

    PMID: 39094294
  14. 14

    Evaluation of time to sputum smear conversion and its association with treatment outcomes among drug-resistant tuberculosis patients: a retrospective record-reviewing study.

    Alzarea AI, Saifullah A, Khan YH, et al.

    Frontiers in pharmacology 2024; (15()):1370344 doi:10.3389/fphar.2024.1370344.

    PMID: 38898922
  15. 15

    Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis.

    Lv L, Li T, Xu K, et al.

    Infection and drug resistance 2018; (11()):147-154 doi:10.2147/IDR.S153499.

    PMID: 29416359
  16. 16

    Assessing Infectiousness and the Impact of Effective Treatment to Guide Isolation Recommendations for People With Pulmonary Tuberculosis.

    Nathavitharana RR, Pearl A, Biewer A, et al.

    The Journal of infectious diseases 2025; (231(1)):10-22 doi:10.1093/infdis/jiae482.

    PMID: 39373221
  17. 17

    Post-TB health and wellbeing.

    Nightingale R, Carlin F, Meghji J, et al.

    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023; (27(4)):248-283 doi:10.5588/ijtld.22.0514.

    PMID: 37035971
  18. 18

    Magnitude and factors associated with post-tuberculosis lung disease in low- and middle-income countries: A systematic review and meta-analysis.

    Maleche-Obimbo E, Odhiambo MA, Njeri L, et al.

    PLOS global public health 2022; (2(12)):e0000805 doi:10.1371/journal.pgph.0000805.

    PMID: 36962784
  19. 19

    Screening for post-TB lung disease at TB treatment completion: Are symptoms sufficient?

    Meghji J, Gunsaru V, Chinoko B, et al.

    PLOS global public health 2024; (4(1)):e0002659 doi:10.1371/journal.pgph.0002659.

    PMID: 38285713
  20. 20

    Effectiveness of pulmonary rehabilitation on functional exercise capacity & health related quality of life (HRQOL) among individuals with post tuberculosis lung disease: A multicentric pre & post-interventional study.

    Sinha S, Titiyal R, Mounika P, et al.

    The Indian journal of medical research 2025; (161(5)):540-551.

    PMID: 40844105
  21. 21

    Culturally adapted pulmonary rehabilitation for adults living with post-tuberculosis lung disease in Kyrgyzstan: protocol for a randomised controlled trial with blinded outcome measures.

    Akylbekov A, Orme MW, Jones AV, et al.

    BMJ open 2022; (12(2)):e048664 doi:10.1136/bmjopen-2021-048664.

    PMID: 35190411

This page provides educational information on monitoring tuberculosis treatment and side effects. Always consult your infectious disease doctor or pulmonologist regarding your medication, symptoms, or isolation guidelines.

Get notified when new evidence is published on Tuberculosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.